All In Biotech

NDA 050638 · Baxter Hlthcare

Penicillin G Potassium In Plastic Container

Penicillin G Potassium · Injection

Last checked: Nov 20, 2026Latest source record: Nov 2, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1990

Jun 25, 1990

Approved uses

1

Original approval plus efficacy supplements

Registered trials

836

181 Phase 3, 88 recruiting

FAERS reports

2,352

1,747 serious, 241 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 24, 2026.

INDICATIONS AND USAGE Therapy Penicillin G Potassium Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 25, 1990 Original approval · Type 3 - New Dosage Form
3 products under this application
  • PENICILLIN G POTASSIUM IN PLASTIC CONTAINER · PENICILLIN G POTASSIUM 60,000 UNITS/ML · INJECTABLE, INJECTION · Prescription
  • PENICILLIN G POTASSIUM IN PLASTIC CONTAINER · PENICILLIN G POTASSIUM 20,000 UNITS/ML · INJECTABLE, INJECTION · Discontinued
  • PENICILLIN G POTASSIUM IN PLASTIC CONTAINER · PENICILLIN G POTASSIUM 40,000 UNITS/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Penicillin G" as an intervention, any sponsor and status, largest first.

All 836 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug hypersensitivity671
  • drug ineffective342
  • rash244
  • dyspnoea243
  • diarrhoea233
  • nausea214
  • off label use209
  • malaise199
  • drug intolerance192
  • abdominal pain upper180
  • cough161
  • headache157

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200418
200520
200629
200757
200829
200937
201028
201145
2012140
201329
201424
201528
201640
201760
2018113
2019141
2020155
2021200
2022296
2023316
2024253
2025196
202698

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 303 on PubMed

Sponsor: Baxter Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.